TR201908296T4 - Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi - Google Patents

Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi Download PDF

Info

Publication number
TR201908296T4
TR201908296T4 TR2019/08296T TR201908296T TR201908296T4 TR 201908296 T4 TR201908296 T4 TR 201908296T4 TR 2019/08296 T TR2019/08296 T TR 2019/08296T TR 201908296 T TR201908296 T TR 201908296T TR 201908296 T4 TR201908296 T4 TR 201908296T4
Authority
TR
Turkey
Prior art keywords
compound
dopa
formula
carbidopa
pharmaceutically acceptable
Prior art date
Application number
TR2019/08296T
Other languages
English (en)
Turkish (tr)
Inventor
Cardinal-David Benoit
S Chan Vincent
E Dempah Kassibla
P Enright Brian
F Henry Rodger
Ho Raimundo
Huang Ye
D Huters Alexander
C Klix Russell
W Krabbe Scott
R Kym Philip
Lao Yanbin
Lou Xiaochun
E Mackey Sean
A Matulenko Mark
T Mayer Peter
P Miller Christopher
Stambuli James
A Voight Eric
Wang Zhi
G Zhang Geoff
J Stella Valentino
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201908296(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of TR201908296T4 publication Critical patent/TR201908296T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2019/08296T 2014-10-21 2015-10-21 Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi TR201908296T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21

Publications (1)

Publication Number Publication Date
TR201908296T4 true TR201908296T4 (tr) 2019-06-21

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08296T TR201908296T4 (tr) 2014-10-21 2015-10-21 Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi

Country Status (37)

Country Link
US (7) US9446059B2 (cg-RX-API-DMAC7.html)
EP (3) EP4186510A1 (cg-RX-API-DMAC7.html)
JP (6) JP6567049B2 (cg-RX-API-DMAC7.html)
KR (3) KR102537018B1 (cg-RX-API-DMAC7.html)
CN (4) CN111494395B (cg-RX-API-DMAC7.html)
AR (1) AR102389A1 (cg-RX-API-DMAC7.html)
AU (4) AU2015335941B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017008198B1 (cg-RX-API-DMAC7.html)
CA (1) CA2965379A1 (cg-RX-API-DMAC7.html)
CY (2) CY1121826T1 (cg-RX-API-DMAC7.html)
DK (1) DK3209302T3 (cg-RX-API-DMAC7.html)
ES (1) ES2739536T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20230014I1 (cg-RX-API-DMAC7.html)
FR (1) FR23C1035I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20191285T1 (cg-RX-API-DMAC7.html)
HU (2) HUE044115T2 (cg-RX-API-DMAC7.html)
IL (3) IL251829B (cg-RX-API-DMAC7.html)
LT (2) LT3209302T (cg-RX-API-DMAC7.html)
LU (1) LUC00304I2 (cg-RX-API-DMAC7.html)
MX (2) MX381069B (cg-RX-API-DMAC7.html)
MY (1) MY189519A (cg-RX-API-DMAC7.html)
NL (1) NL301224I2 (cg-RX-API-DMAC7.html)
NO (1) NO2023013I1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500746B1 (cg-RX-API-DMAC7.html)
PL (1) PL3209302T3 (cg-RX-API-DMAC7.html)
PT (1) PT3209302T (cg-RX-API-DMAC7.html)
RS (1) RS58972B1 (cg-RX-API-DMAC7.html)
RU (2) RU2743347C2 (cg-RX-API-DMAC7.html)
SA (1) SA521421115B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703170RA (cg-RX-API-DMAC7.html)
SI (1) SI3209302T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900376T1 (cg-RX-API-DMAC7.html)
TR (1) TR201908296T4 (cg-RX-API-DMAC7.html)
TW (2) TWI755257B (cg-RX-API-DMAC7.html)
UA (1) UA120437C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016065019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702760B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
SG11201703170RA (en) 2014-10-21 2017-05-30 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
EP4295909A3 (en) * 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
WO2017223182A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
AR113908A1 (es) 2017-11-24 2020-06-24 H Lundbeck As Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
CN113015531A (zh) * 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) * 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
EP1030853A1 (en) * 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
EP1541579A1 (en) 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
AU2004270174B2 (en) 2003-08-29 2010-05-20 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
JP2007509973A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増強された吸収のための組成物および投与形態物
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
MXPA06015108A (es) 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
PT1959948E (pt) * 2005-12-05 2012-09-12 Xenoport Inc Mesilato de pró-fármaco de levodopa, suas composições e suas utilizações
UA95954C2 (ru) * 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
TW200843732A (en) 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
RU2485947C2 (ru) * 2008-02-06 2013-06-27 Вокхардт Рисерч Сентер Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
ES2627655T3 (es) 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
AU2010315892B2 (en) 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
SMT201800145T1 (it) 2010-11-15 2018-05-02 Neuroderm Ltd Somministrazione continua di l-dopa, di inibitori della dopa decarbossilasi, di inibitori della catecol-o-metil trasferasi e composizioni per essa
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
US20140088192A1 (en) 2010-12-10 2014-03-27 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
SG11201703170RA (en) 2014-10-21 2017-05-30 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP4295909A3 (en) 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
CY2023010I2 (el) 2023-06-09
US20160106765A1 (en) 2016-04-21
AU2015335941B2 (en) 2021-04-01
TWI755257B (zh) 2022-02-11
TW202131931A (zh) 2021-09-01
SI3209302T1 (sl) 2019-06-28
MX2021003840A (es) 2022-06-30
AR102389A1 (es) 2017-02-22
JP2023174770A (ja) 2023-12-08
NO2023013I1 (no) 2023-03-20
RS58972B1 (sr) 2019-08-30
CN107206013A (zh) 2017-09-26
CN111454290A (zh) 2020-07-28
PH12017500746A1 (en) 2017-10-30
NL301224I1 (cg-RX-API-DMAC7.html) 2023-03-29
WO2016065019A1 (en) 2016-04-28
IL268885B (en) 2020-08-31
PT3209302T (pt) 2019-07-19
RU2021103000A (ru) 2021-03-01
EP3209302A1 (en) 2017-08-30
US9446059B2 (en) 2016-09-20
IL251829A0 (en) 2017-06-29
KR102537018B1 (ko) 2023-05-30
CA2965379A1 (en) 2016-04-28
FIC20230014I1 (fi) 2023-03-31
JP2021183628A (ja) 2021-12-02
US20220153765A1 (en) 2022-05-19
LUC00304I2 (cg-RX-API-DMAC7.html) 2025-09-22
US20230106081A1 (en) 2023-04-06
JP6750076B2 (ja) 2020-09-02
SG11201703170RA (en) 2017-05-30
US20180079762A1 (en) 2018-03-22
CN111362980A (zh) 2020-07-03
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
PL3209302T3 (pl) 2019-10-31
ZA201702760B (en) 2022-05-25
LT3209302T (lt) 2019-06-10
IL276493A (en) 2020-09-30
AU2015335941A1 (en) 2017-05-04
SMT201900376T1 (it) 2019-09-09
RU2743347C2 (ru) 2021-02-17
LTPA2023519I1 (cg-RX-API-DMAC7.html) 2023-06-26
AU2021201414A1 (en) 2021-03-25
JP7688087B2 (ja) 2025-06-03
EP3209302B1 (en) 2019-04-24
CN111454290B (zh) 2022-12-23
NZ769153A (en) 2024-04-26
RU2017117413A3 (cg-RX-API-DMAC7.html) 2019-05-30
MX2017005236A (es) 2017-07-26
US10730895B2 (en) 2020-08-04
FR23C1035I2 (fr) 2025-04-18
NL301224I2 (nl) 2023-08-16
US20190375770A1 (en) 2019-12-12
EP3569587A1 (en) 2019-11-20
LTC3209302I2 (cg-RX-API-DMAC7.html) 2025-10-10
AU2023210650A1 (en) 2023-08-24
EP4186510A1 (en) 2023-05-31
ES2739536T3 (es) 2020-01-31
IL251829B (en) 2019-09-26
JP2017537066A (ja) 2017-12-14
US11091507B2 (en) 2021-08-17
AU2021201414B2 (en) 2023-05-11
UA120437C2 (uk) 2019-12-10
BR112017008198B1 (pt) 2021-02-09
SA521421115B1 (ar) 2022-03-01
CN111494395B (zh) 2024-06-21
CN111494395A (zh) 2020-08-07
US10174061B2 (en) 2019-01-08
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
NZ730996A (en) 2024-04-26
JP2019218356A (ja) 2019-12-26
DK3209302T3 (da) 2019-05-13
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
JP2020189864A (ja) 2020-11-26
HUS2300009I1 (hu) 2023-03-28
JP2025118978A (ja) 2025-08-13
RU2017117413A (ru) 2018-11-26
CN111362980B (zh) 2022-10-18
CY1121826T1 (el) 2020-07-31
TWI718999B (zh) 2021-02-21
HRP20191285T1 (hr) 2019-10-18
MX381069B (es) 2025-03-12
KR20170071599A (ko) 2017-06-23
KR20240113982A (ko) 2024-07-23
MY189519A (en) 2022-02-16
US20200262852A1 (en) 2020-08-20
MX393568B (es) 2025-03-24
JP6567049B2 (ja) 2019-08-28
PH12017500746B1 (en) 2021-12-15
US20160362431A1 (en) 2016-12-15
TW201630924A (zh) 2016-09-01
IL268885A (en) 2019-10-31
AU2025238004A1 (en) 2025-10-16

Similar Documents

Publication Publication Date Title
TR201908296T4 (tr) Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi
US20240024338A1 (en) Carbidopa and l-dopa prodrugs and methods of use
HK40092679A (en) Intermediates and process for preparing l-dopa diphosphate
HK40017405A (en) Intermediates and process for preparing l-dopa diphosphate
HK40034110B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease